Key result
ACTN4 gene knock-out in H1299 non-small cell lung carcinoma cells increased resistance to topoisomerase II inhibitors by enhancing non-homologous end joining and suppressing homologous recombination.
Why the study?
ACTN4 is associated with poor cancer prognosis but serves as a positive marker for platinum-based adjuvant chemotherapy in NSCLC, prompting investigation into its role in NSCLC cellular response to genotoxic drugs.
ACTN4 knock-out in NSCLC cells increases resistance to topoisomerase II inhibitors by enhancing non-homologous end joining and suppressing homologous recombination.
Answers are grounded in this paper and cite their sources.
ACTN4 knockout may modulate NSCLC chemosensitivity; leaves open its value as biomarker or target pending clinical studies.
BACKGROUND: ACTN4 is an actin-binding protein involved in many cellular processes, including cancer development. High ACTN4 expression is often associated with a poor prognosis. However, it has been identified as a positive marker for platinum-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC). The goal of our study was to investigate the involvement of ACTN4 in the NSCLC cells' response to the genotoxic drugs. RESULTS: We generated H1299 cells with the ACTN4 gene knock-out (ACTN4 KO), using the CRISPR/Cas9 system. The resistance of the cells to the cisplatin and etoposide was analyzed with the MTT assay. We were also able to estimate the efficiency of DNA repair through the DNA comet assay and gamma-H2AX staining. Possible ACTN4 effects on the non-homologous end joining (NHEJ) and homologous recombination (HR) were investigated using pathway-specific reporter plasmids and through the immunostaining of the key proteins. We found that the H1299 cells with the ACTN4 gene knock-out did not show cisplatin-resistance, but did display a higher resistance to the topoisomerase II inhibitors etoposide and doxorubicin, suggesting that ACTN4 might be somehow involved in the repair of DNA strand breaks. Indeed, the H1299 ACTN4 KO cells repaired etoposide- and doxorubicin-induced DNA breaks more effectively than the control cells. Moreover, the ACTN4 gene knock-out enhanced NHEJ and suppressed HR efficiency. Supporting the data, the depletion of ACTN4 resulted in the faster assembly of the 53BP1 foci with a lower number of the phospho-BRCA1 foci after the etoposide treatment. CONCLUSIONS: Thus, we are the first to demonstrate that ACTN4 may influence the resistance of cancer cells to the topoisomerase II inhibitors, and affect the efficiency of the DNA double strand breaks repair. We hypothesize that ACTN4 interferes with the assembly of the NHEJ and HR complexes, and hence regulates balance between these DNA repair pathways.
No takes yet. Share an insight, caveat, or question.
Kriger et al. (2022) studied Non-small cell lung cancer (NSCLC). ACTN4 gene knock-out vs. Wild-type/control cells was evaluated on Resistance to topoisomerase II inhibitors and efficiency of DNA double-strand break repair. ACTN4 gene knock-out in H1299 non-small cell lung carcinoma cells increased resistance to topoisomerase II inhibitors by enhancing non-homologous end joining and suppressing homologous recombination.
Synapse has enriched 10 related papers. Consider them for comparative context: